Metro International Biotech is a privately-owned clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary NAD+ precursors in the world.
NAD+ levels have been shown to decline as humans age and increasing NAD+ to preserve health and normal metabolism is believed to have broad therapeutic potential. Metro International Biotech has assembled a team of industry-leading scientists to drive its lead compound, MIB-626, through clinical development and fuel the Company’s robust R&D engine, building a library of next-generation analogs with tissue-selective NAD+ increasing properties.
To enable longer, healthier lives.
Since its founding, Metro International Biotech has built a world class, highly collaborative team of leading NAD+ experts, with extensive clinical and corporate experience, as well as in related fields such as metabolic pathways, drug development and manufacturing, molecular biology, isotopic labeling and nucleoside chemistry.
Edward Schulak, Chairman
David J. Livingston, MBA, Ph.D., Chief Scientific Officer
Kyle Meetze, MBA, Chief Business Officer
Michael Willis, Ph.D., JD, Corporate Counsel
David Sinclair, Ph.D., SAB Chair and Co-Founder
Anthony Sauve, Ph.D., Co-Founder
Rajendra Apte, M.D., Ph.D., Co-Founder
James Ellis, Ph.D., SAB Member
Lindsay Wu, Ph.D., SAB Member
Johan Auwerx, M.D., Ph.D., SAB Member
Nick Lane, Ph.D., SAB Member
Neil Flanzraich, JD., SAB Member
What We've Achieved
Manufacturing a naturally occurring proprietary human clinical grade NAD+ enhancer
Designed and synthesized over 100 novel NAD+ enhancers, screened for optimal therapeutic properties
Gathered robust preclinical data supporting the broad therapeutic potential of modulating NAD+
Developed solid oral dosage formulations of MIB-626, with scalable manufacturing capabilities
Protected extensive IP portfolio, with 21 patent families and in-house proprietary R&D
Ongoing Phase 1 trials at a leading hospital in Boston